Not Your Grandfather’s Cytokine: Antibody Engineering After Gazyva
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche lays out plans for building on its glyco-engineered antibodies to support and eventually activate T-cell responses, including an IL-2 variant immunocytokine.